Clazosentan

• CAT Number: R059607
• CAS Number: 180384-56-9
• Molecular Formula: C25H23N9O6S
• Molecular Weight: 577.57
• Purity: ≥95%
• Synonyms: N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2H-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
• InChI: InChI=1S/C25H23N9O6S/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23/h3-10,13-14,35H,11-12H2,1-2H3,(H,28,29,32)(H,30,31,33,34)
• InChIKey: LFWCJABOXHSRGC-UHFFFAOYSA-N
• SMILES: CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC

Clazosentan（Cat No.:R059607）is an investigational selective endothelin A receptor antagonist, primarily being studied for its potential in treating conditions associated with vasospasm, such as subarachnoid hemorrhage (SAH). Endothelin A receptors play a key role in regulating blood vessel constriction, and by blocking these receptors, Clazosentan aims to reduce vasospasm, prevent subsequent brain injury, and improve patient outcomes after SAH. It has demonstrated promise in clinical trials by reducing the incidence of delayed cerebral ischemia. Ongoing research is focused on evaluating its safety, efficacy, and potential in other vascular-related diseases.